格隆汇12月9日丨东亚药业(605177.SH)公布，本次结项的募投项目名称："特色新型药物制剂研发与生 产基地建设项目（一期）"及"年产3,685吨医药及中间体、4,320吨副产盐项目（一期）"（以下统称"募 投项目"）。本次节余金额为14,732.34万元，下一步的安排是：鉴于上述募投项目已全部实施完毕并达 到预定可使用状态，为合理配置资金，提高募集资金使用效率，结合公司实际情况，浙江东亚药业股份 有限公司（以下简称"公司"）拟将节余募集资金14,732.34万元（含利息手续费等，实际金额以资金转出 当日募集资金专户余额为准）永久性补充流动资金，用于公司日常生产经营。 ...

Group 1 - The core project names are "Research and Production Base Construction Project for Specialty New Drug Formulations (Phase I)" and "Annual Production of 3,685 tons of Pharmaceuticals and Intermediates, 4,320 tons of By-product Salts Project (Phase I)" [1] - The remaining amount of funds is 147.32 million yuan, which will be permanently used to supplement working capital for daily operations [1] - The company has completed the above fundraising projects and they have reached the intended usable status [1]